ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
0,00%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,895
0,36%
Bitcoin
67 117,83
1,27%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Incyte Corporation (INCY)

  7. Incyte Corporation (INCY) Actualités

INCY

Incyte (INCY)

Incyte Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:INCY
DateHeureSourceTitreSymboleSociété
16/05/202403h45Business WireIncyte präsentiert Daten aus seinem Onkologie-Portfolio beim Jahrestreffen 2024 der ASCO und beim EHA2024 CongressNASDAQ:INCYIncyte Corporation
15/05/202417h44Business WireIncyte présentera les données de son portefeuille d'oncologie lors de la réunion annuelle 2024 de l'ASCO et du congrès EHA2024NASDAQ:INCYIncyte Corporation
15/05/202417h10Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:INCYIncyte Corporation
14/05/202423h00Business WireIncyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 CongressNASDAQ:INCYIncyte Corporation
14/05/202415h05IH Market NewsProducer Price Inflation Data May Weigh On Wall StreetNASDAQ:INCYIncyte Corporation
14/05/202400h06Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:INCYIncyte Corporation
13/05/202422h34IH Market NewsDow Snaps Eight-Day Winning Streak After Lackluster SessionNASDAQ:INCYIncyte Corporation
13/05/202417h19Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:INCYIncyte Corporation
13/05/202413h19Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:INCYIncyte Corporation
13/05/202413h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
13/05/202413h00Business WireIncyte Announces Intention to Buy Back up to $2.0 Billion of its Common StockNASDAQ:INCYIncyte Corporation
10/05/202400h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
02/05/202414h00Business WireIncyte to Present at Upcoming Investor ConferenceNASDAQ:INCYIncyte Corporation
30/04/202413h00Business WireIncyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsNASDAQ:INCYIncyte Corporation
24/04/202400h11Business WireIncyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorieNASDAQ:INCYIncyte Corporation
24/04/202400h01Business WireIncyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekanntNASDAQ:INCYIncyte Corporation
23/04/202413h00Business WireIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR AntagonistsNASDAQ:INCYIncyte Corporation
11/04/202414h00Business WireIncyte to Report First Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
01/04/202414h30Business WireIncyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast AsiaNASDAQ:INCYIncyte Corporation
29/03/202421h30Business WireIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
11/03/202413h57Business WireIncyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modéréeNASDAQ:INCYIncyte Corporation
11/03/202413h57Business WireIncyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura®) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekanntNASDAQ:INCYIncyte Corporation
11/03/202411h06Business WireIncyte présente de nouvelles données de l’étude de phase 2 évaluant le povorcitinib chez des patients atteints de prurigo nodulaireNASDAQ:INCYIncyte Corporation
11/03/202410h53Business WireIncyte legt neue brandaktuelle Daten aus Phase-2-Studie zur Prüfung von Povorcitinib bei Patienten mit Prurigo nodularis vorNASDAQ:INCYIncyte Corporation
10/03/202421h05Business WireIncyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo NodularisNASDAQ:INCYIncyte Corporation
10/03/202421h05Business WireIncyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis SuppurativaNASDAQ:INCYIncyte Corporation
04/03/202420h38Business WireDe nouvelles données dérivées du portefeuille dermatologique croissant d’Incyte seront présentées lors de l’assemblée annuelle 2024 de l’American Academy of Dermatology (AAD)NASDAQ:INCYIncyte Corporation
04/03/202420h02Business WireNeue Daten aus dem wachsenden Dermatologieportfolio von Incyte werden bei Jahresversammlung 2024 der American Academy of Dermatology (AAD) präsentiertNASDAQ:INCYIncyte Corporation
04/03/202414h00Business WireNew Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:INCYIncyte Corporation
29/02/202416h19Business WireIncyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AINASDAQ:INCYIncyte Corporation
 Showing the most relevant articles for your search:NASDAQ:INCY

Dernières Valeurs Consultées

NASDAQ
SMXT
SolarMax Technology
NASDAQI
FN35GI
First North Real Estate GI
LSE
XT01
X Us T Ushort
EU
FR001400OOH6
Auto ABS French Loans 20...
AQEU
REP
Colas
ASX
WES
Wesfarmers
AMEX
JFP
ASX
FGG
Future Generation Global
CSE
BGX
BGX Black Gold Exploration
TG
7ZG
Askari Metals
TG
A6T
Artec Technologies O N
BFNX
ELFETH
TSXV
MILL
Millbank Mining
COIN
ARKMBTC
Arkham
TG
3A01
Amyris
BIT
TRUD
Exchange Traded Fund Ivz...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés